Recombinant Human Siglec-1/CD169 Protein，His

Siglec-1, also known as CD169, is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, primarily expressed on macrophages and dendritic cells. It plays a crucial role in the immune system by facilitating the recognition and internalization of sialylated pathogens, thus influencing immune responses. The study of Siglec-1/CD169 has gained significant attention due to its potential applications in immunotherapy and vaccine development. Research indicates that this receptor not only participates in pathogen recognition but also modulates the interaction between immune cells and tumor microenvironments. Understanding the structural features and function of Siglec-1/CD169 through recombinant protein studies can provide insights into its role in immune regulation and its potential as a biomarker for certain diseases. Furthermore, the ability to produce recombinant Siglec-1/CD169 protein allows for the exploration of its binding affinities and therapeutic efficacy in various contexts, such as enhancing vaccine responses or targeting tumor cells. The ongoing research aims to unravel the complexities of Siglec-1/CD169 interactions and its implications in both innate and adaptive immunity, positioning it as a promising target for future therapeutic strategies. Through these investigations, scientists hope to harness the mechanisms of Siglec-1/CD169 to improve disease outcome and develop innovative approaches to combat infections and cancer.